Nivolumab

證據等級: L5

預測適應症: 10 個

Nivolumab: From Melanoma to Non-Cutaneous Melanoma Subtypes

One-Sentence Summary

Nivolumab is an anti-PD-1 immune checkpoint inhibitor already established in the treatment of melanoma. The TxGNN model predicts it may also be effective for non-cutaneous melanoma — a heterogeneous group covering mucosal, ocular, anorectal and other rare melanoma sites — with 50 clinical trials and 8 publications currently identified in support of this direction (though most were designed for melanoma broadly rather than this subtype specifically).

Data note: This evidence pack shows no ARTG entry and no TFDA/TGA Product Information on file for Nivolumab (market status: “not marketed”, 0 licences). Given Nivolumab (Opdivo®) is a well-established, internationally approved therapy, this most likely reflects a gap in the underlying data collection rather than true absence from the Australian market — this should be verified directly against the TGA ARTG register before this report is used for any decision.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack — no ARTG-listed indication text was returned (see data note above)
Predicted New Indication	Non-cutaneous melanoma
TxGNN Prediction Score	98.41%
Evidence Level	L2
Australia Market Status	Not marketed (per this evidence pack — recommend independent TGA verification)
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the supporting evidence that is available, Nivolumab is a fully human anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 interaction, restoring T-cell mediated anti-tumour immunity. This mechanism is already well established in melanoma treatment generally — the evidence pack’s own rationale notes it is “已核准用於黑色素瘤整體治療” (approved for melanoma treatment overall) in multiple jurisdictions.

“Non-cutaneous melanoma” is not a distinct disease but an umbrella term for melanoma arising outside typical sun-exposed skin — mucosal, ocular/uveal, anorectal, and other rare primary sites. Mechanistically, PD-1 expression and immune evasion pathways are shared across melanoma subtypes, so the rationale for extending Nivolumab’s use is biologically plausible.

However, the evidence base is markedly weaker than for cutaneous melanoma. Non-cutaneous subtypes generally carry a lower tumour mutational burden (TMB) and have historically shown inferior response rates to checkpoint inhibition. Much of the supporting evidence identified here is real-world/observational data, basket trials that enrol non-cutaneous melanoma alongside other rare tumours, or individual case reports — rather than subtype-specific randomised trials. This heterogeneity is the main reason the evidence level sits at L2 rather than L1, despite the large trial volume.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT02599402	Phase 3	Completed	533	CheckMate 401: nivolumab + ipilimumab followed by nivolumab monotherapy vs. combination alone, first-line in unresectable/metastatic melanoma
NCT07221734	Phase 3	Recruiting	632	LEON study: biosimilar MB11 vs. reference Opdivo® in previously untreated advanced melanoma
NCT02990611	N/A (non-interventional)	Completed	1,087	Large national real-world study of nivolumab ± ipilimumab in advanced/adjuvant melanoma settings
NCT03767348	Phase 1/2	Active, not recruiting	340	IGNYTE: RP1 oncolytic virus + nivolumab in unresectable melanoma, MSI-H/dMMR tumours and non-melanoma skin cancer
NCT03235245	Phase 2	Active, not recruiting	271	EBIN (EORTC): sequential targeted therapy then nivolumab+ipilimumab vs. immediate combination immunotherapy in BRAF V600-mutant melanoma
NCT02977052	Phase 2	Unknown	186	OpACIN-neo: optimal neoadjuvant dosing schedule of ipilimumab + nivolumab in stage III melanoma
NCT02637531	Phase 1	Unknown	219	IPI-549 monotherapy and combined with nivolumab in advanced solid tumours, including melanoma
NCT03645928	Phase 2	Recruiting	245	Autologous tumour-infiltrating lymphocyte (TIL) therapy combined with checkpoint inhibitors in solid tumours
NCT04462406	Phase 2	Active, not recruiting	150	PET-Stop: biomarker-driven early discontinuation of anti-PD-1 therapy in advanced melanoma
NCT02593786	Phase 1/2	Completed	58	CheckMate 077: nivolumab safety/efficacy in Chinese patients with previously treated advanced/recurrent solid tumours (incl. melanoma)

40 additional trials were identified but are not shown here; most are melanoma trials generally rather than non-cutaneous-subtype-specific studies.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26841210	2016	Cohort	J Eur Acad Dermatol Venereol	Single-institution comparison of nivolumab outcomes in cutaneous vs. non-cutaneous melanoma
37887546	2023	Cohort	Curr Oncol	Retrospective multi-centre comparison of anti-PD-1 ± ipilimumab outcomes by age group in advanced melanoma
30510916	2018	Biomarker study	Front Oncol	Serum soluble CD163 explored as a predictive marker of nivolumab response in advanced cutaneous melanoma
30549256	2019	Cohort	Int J Rheum Dis	Development of rheumatic immune-related adverse events associated with good oncological response to PD-1 inhibition
41774417	2025	Case series	Pigment Cell Melanoma Res	Molecular profiling of epidermotropic metastatic melanoma in a patient on adjuvant nivolumab
28171845	2017	Case Report	Int J Surg Case Rep	First reported case of metastatic anorectal amelanotic melanoma responding markedly to nivolumab
34176837	2022	Case Report	Intern Med (Tokyo)	Mediastinal (non-cutaneous) malignant melanoma showing marked shrinkage on nivolumab monotherapy
40236344	2025	Case Report	Cureus	Metastatic melanoma in the transverse colon, managed with surgical resection and systemic immunotherapy

Australia Market Information

Currently no ARTG entries are recorded for Nivolumab in this evidence pack. Given Nivolumab is internationally approved and marketed (as Opdivo®), this is likely a data collection gap rather than genuine market absence — please verify directly against the TGA ARTG register before relying on this field.

Cytotoxicity

Nivolumab is an antineoplastic agent (used across multiple cancer indications, including melanoma), so this section applies — however, it is not a conventional cytotoxic chemotherapy agent; it is a checkpoint-inhibitor immunotherapy, which has a materially different toxicity profile.

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 immune checkpoint inhibitor) — not conventional cytotoxic chemotherapy
Myelosuppression Risk	Low — myelosuppression is not a characteristic toxicity of PD-1 blockade; please refer to the PI for confirmed haematological safety data
Emetogenicity Classification	Low — checkpoint inhibitors are not classically emetogenic, unlike cytotoxic chemotherapy
Monitoring Items	Immune-related adverse event (irAE) surveillance rather than standard cytotoxic monitoring — literature identified in this pack reports myocarditis, colitis, pneumonitis and rheumatic irAEs with nivolumab; thyroid function, liver function, and clinical symptoms of colitis/pneumonitis/myocarditis should be monitored
Handling Protection	As a monoclonal antibody, standard cytotoxic drug handling precautions (e.g. closed-system transfer devices) do not automatically apply — follow institutional biologic/monoclonal antibody infusion protocols and the TGA-approved PI

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information — this evidence pack contains no populated key warnings, contraindications, or drug interaction data for Nivolumab (all fields returned as data gaps; DDI query status: not found). This is flagged as a Blocking data gap (DG001) that must be resolved before any formal safety assessment.

Separately, literature identified during this evidence review (outside the formal safety fields) reported immune-related adverse events with nivolumab, including fulminant myocarditis, colitis, and pneumonitis — consistent with the known irAE profile of PD-1 inhibitors generally, and worth flagging for clinical awareness pending full PI review.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic rationale is sound (shared PD-1 pathway across melanoma subtypes) and one completed Phase 3 RCT (CheckMate 401) plus a large body of trial and real-world evidence supports Nivolumab in melanoma broadly. However, evidence specific to non-cutaneous subtypes is largely indirect — drawn from basket trials, retrospective cohorts, and case reports — rather than subtype-dedicated randomised trials, and known biological differences (lower TMB, generally lower response rates) mean efficacy cannot be assumed to transfer directly from cutaneous melanoma.

To proceed, the following is needed:

TFDA/TGA-approved Product Information — warnings, precautions and contraindications (Blocking gap, DG001)
Mechanism of action documentation from DrugBank or equivalent source (DG002)
Independent verification of actual TGA/ARTG registration status for Nivolumab in Australia, given the discrepancy between this evidence pack and its well-established international approval
Subtype-specific efficacy data (e.g. dedicated mucosal, uveal, or anorectal melanoma trial results) to narrow the current heterogeneous “non-cutaneous melanoma” grouping
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.